ROCHE’S ENICEPATIDE CUTS WEIGHT 15.5%, NORMALIZES BLOOD SUGAR IN 62% OF PATIENTS IN PHASE II Roche reported positive 48-week Phase II results for enicepatide, its once-weekly dual GLP-1/GIP drug for people with type 2 diabetes and overweight or obesity. At the highest 24 mg dose, patients lost an average 15.5% of body weight, with Roche saying weight loss had not yet plateaued. HbA1c fell 2.65 percentage points from an 8.1% baseline. By week 48, 90% of patients on the highest dose reached the diabetes treatment target of HbA1c ≤6.5%, while 62% reached non-diabetic blood sugar levels below 5.7%. Safety was consistent with the incretin drug class, with mostly mild-to-moderate gastrointestinal side effects and a 2% discontinuation rate due to adverse events. Enicepatide targets the same GLP-1/GIP receptors as Eli Lilly’s tirzepatide. Roche already has two Phase III weight-management trials underway and plans Phase III diabetes and cardiovascular-outcomes programs beginning in H1 2027.